Krishna Yeshwant

Background

Krishna Yeshwant is a Managing Partner at GV (formerly Google Ventures), where he co-leads the firm’s life sciences group ¹. He is a physician, programmer, and entrepreneur whose career bridges technology and medicine ¹.

Yeshwant is the son of two Chicago physicians ². He majored in computer science at Stanford University ¹. Early in his career, he co-founded two technology companies: an electronic data interchange company that was acquired by Hewlett-Packard, and a network security company that was acquired by Symantec ¹.

His path into medicine began in 2002 when he worked with surgeons at Massachusetts General Hospital and Brigham and Women’s Hospital (BWH) in Boston, writing software to use imaging systems to guide surgical procedures ². He went on to earn his M.D. from Harvard Medical School and his MBA from Harvard Business School, graduating in 2009 ^{3 4}. He completed his residency and continues to practice as an attending physician in internal medicine at Brigham and Women’s Hospital ^{1 5}.

Yeshwant joined Google in 2008 in new business development ⁶. He was part of the founding team of GV and led the fund’s early commitment to investing in life sciences ¹. He has served as a General Partner since June 2009 and is now a Managing Partner ⁶.

He also established GV’s incubation program, which helped start companies including Verve Therapeutics and ROME Therapeutics ¹.

Stated Thesis

Yeshwant publicly describes his investment interest as spanning the entire healthcare spectrum, including care delivery, health IT, devices, diagnostics, payor/provider dynamics, and therapeutics ¹. He has stated that most of his investments sit at the intersection of life sciences and data sciences ².

On GV’s healthcare approach, Yeshwant has said: “A third of our fund is now dedicated to life sciences, and everyone on the team feels strongly that the health system is broken in so many ways” ⁷. He has emphasized the importance of his team’s medical expertise: “It’s all about the team, which is comprised of doctors and science Ph.D.s. Multiple investors in our group, myself included, are currently practicing medicine. We understand how the science development cycles work, the patient pain-points, and the complexity, and we don’t shy away from it” ⁷.

Yeshwant has been vocal about the need for better science funding models, stating: “The way we finance things in science is just completely crazy,” contrasting the ease of raising venture capital as an entrepreneur with the hundreds of pages of grant material scientists must submit for modest funding ⁸.

He has identified precision medicine, immunotherapy, gene editing (CRISPR), and the microbiome as major areas of focus ^{7 8}. On the microbiome specifically, he has said: “This is one of the few emerging areas that will be as big as gene-editing” ⁷.

Inferred Thesis

Based on 22 verified investments below, Yeshwant’s actual portfolio reveals a deep concentration in healthcare and life sciences with a strong preference for companies applying technology or data science to biological and clinical problems.

Sector distribution (based on 22 verified investments): - Therapeutics/biotech (drug discovery, gene editing, gene therapy): 12 of 22 (55%) — Beam Therapeutics, Relay Therapeutics, Verve Therapeutics, ROME Therapeutics, insitro, EQRx, LifeMine Therapeutics, Encoded Therapeutics, Ventus Therapeutics, Sana Biotechnology, Decibel Therapeutics, Parabilis Medicines - Health IT / care delivery: 5 of 22 (23%) — Flatiron Health, One Medical, Aledade, Quartet Health, Verana Health - Diagnostics / genomics platforms: 3 of 22 (14%) — Foundation Medicine, DNAnexus, Freenome - Clinical trials / research tools: 1 of 22 (5%) — Science 37 - Consumer health: 1 of 22 (5%) — Nanit

Stage distribution: Yeshwant typically invests at Series A and Series B. His flagship investments (Flatiron Health, Foundation Medicine, Verve Therapeutics, ROME Therapeutics) were often at the earliest institutional round, with GV frequently serving as lead investor ^{9 10 11}. His check size ranges from $250K to $50M with a sweet spot around $25M ⁶.

Geographic concentration: Investments are heavily concentrated in Boston/Cambridge, MA, consistent with the biotech ecosystem around Harvard, MIT, and the Broad Institute. Several portfolio companies (Flatiron Health, Aledade) are based in New York and the DC area.

Founder profile patterns: Yeshwant gravitates toward scientist-founders and technical co-founders with deep domain expertise. Many portfolio companies were founded by professors, physicians, or scientists (Daphne Koller at insitro, Sekar Kathiresan at Verve, Rosana Kapeller at ROME, Farzad Mostashari at Aledade). He has stated that the key quality he looks for is empathy ².

Co-investor patterns: ARCH Venture Partners, Third Rock Ventures, and F-Prime Capital appear repeatedly across his life sciences portfolio (Verve, Beam, Foundation Medicine). Andreessen Horowitz has co-invested on several deals (insitro, EQRx). First Round Capital appeared in his earlier health IT investments (Flatiron Health, DNAnexus).

Notable pattern — incubation model: Unlike most VCs, Yeshwant has built an incubation capability at GV, working with scientists to form companies from scratch rather than waiting for inbound pitches. Verve Therapeutics and ROME Therapeutics both emerged from this model ^{1 11 12}.

Gap between stated and actual thesis: Despite claiming interest across the “entire healthcare spectrum” including consumer health, his portfolio is overwhelmingly concentrated in therapeutics and clinical data platforms. Consumer health investments are minimal (only Nanit identified). His stated hope for “something as big as Google for consumer health” ⁷ has not yet translated into significant portfolio allocation.

Portfolio

This table represents a partial view of Yeshwant’s portfolio. According to NFX Signal, he has approximately 48 investments on record ⁶. The 22 companies above represent roughly 46% of his known total. Several entries lack specific round years because only board membership or portfolio inclusion could be confirmed, not the specific investment date.

In Their Own Words

On Flatiron Health’s mission: “Flatiron is doing for cancer data what Google did for information on the Internet — organizing it and making it useful so physicians and researchers can improve the way we treat disease” ⁹.

On evaluating founding teams: “It’s rare to find a team of the caliber assembled by Flatiron Health that combines pragmatic insights from healthcare with deep technical insight” ¹⁴.

On the intersection of tech and medicine: “That experience was transformative because I learned how much we can accomplish if we bring the tech and medical worlds together” ².

On science funding: “The way we finance things in science is just completely crazy.” He noted that as an entrepreneur he could “write a 10-page deck and raise tens of millions of dollars,” while laboratory researchers must submit “hundreds of pages of grant material just to get a couple of hundreds of thousand dollars” ⁸.

On consumer health: “I hope we see something as big as Google for consumer health” ⁷.

On the microbiome: “Everyone experiences a drug or food differently because of the microbiome. This is one of the few emerging areas that will be as big as gene-editing” ⁷.

On Foundation Medicine: “We see a significant market opportunity for Foundation Medicine’s cancer diagnostic test” ¹⁰.

On Aledade: “The company’s physician-led model will become even more valuable as commercial payers continue to implement new payment models” ¹⁶.

On EQRx: Yeshwant stated that EQRx’s model will “deliver a sustainable approach for creating, reinvesting in and rewarding therapeutics innovation, while ensuring these new medicines are broadly accessible to people and healthcare systems through dramatically lower pricing” ²⁰.

On DNAnexus: “Their vision of revolutionizing the field of bioinformatics is extremely compelling, and has the potential to change DNA management” ¹³.

On the biotech market reset (2024): “Things seem to be back toward where we expect them. It feels much more calibrated to where the science is and how things are going” ²³.

On the future of therapeutics: “We can see a path to not just treating, but curing more diseases. It’s going to be transformative” ¹.

What Founders Say

No independently sourced founder testimonials found. Dedicated searches for founder quotes about Krishna Yeshwant did not surface direct testimonials from portfolio company founders about their experience working with him. Nat Turner of Flatiron Health has spoken positively about the GV partnership broadly but no direct quotes specifically about Yeshwant as an investor were found.

Anthony Philippakis, a GV colleague and co-founder of Verve Therapeutics, has described meeting Yeshwant as “one of the most defining elements of his career,” highlighting Yeshwant’s significant influence on those around him ².

Connections

• Board member, Flatiron Health — joined board at Series A alongside Nat Turner (CEO) and Zach Weinberg (co-founder) ⁹. Flatiron was acquired by Roche for $1.9B in 2018 ²⁴.
• Former board member, Foundation Medicine — joined board at Series A in 2011 alongside Third Rock Ventures and Kleiner Perkins ¹⁰.
• Independent Director, Verve Therapeutics — board member since founding; company incubated at GV ^{3 11}.
• Director, ROME Therapeutics — board member since founding; company incubated at GV ^{3 12}.
• Director, LifeMine Therapeutics ²².
• Director, DNAnexus — joined board at Series B in 2011 ^{3 13}.
• Director, Quartet Health ³.
• Director, Verana Health ³.
• Director, Parabilis Medicines ³.
• Director, Spotlight Therapeutics ³.
• Board Observer, insitro — alongside Daphne Koller (CEO), with co-investors Andreessen Horowitz, ARCH Venture Partners, Third Rock Ventures ²⁵.
• Attending Physician, Brigham and Women’s Hospital — practices internal medicine part-time since 2009 ^{1 5}.
• Faculty, Harvard Medical School / Center for Primary Care ²⁶.
• Frequent co-investor with Anthony Philippakis (GV General Partner, former Broad Institute Chief Data Officer), who co-leads GV’s life sciences practice ²³.

Sources